gmp
gmp

Find Novel Gastroenterology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KB295

            Therapeutic Area: Gastroenterology Product Name: KB295

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2020

            Details:

            In ex vivo studies, KB295 has demonstrated the ability to increase the production of short chain fatty acids and suppress the growth of inflammatory bacteria such as Enterobacteriaceae.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab

            Therapeutic Area: Gastroenterology Product Name: TZLS-401

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ThinkEquity

            Deal Size: $57.2 million Upfront Cash: Undisclosed

            Deal Type: Public Offering August 05, 2020

            Details:

            Tiziana intends to use the net proceeds to advance the clinical development of Foralumab, to initiate a trial in HCC patients with Milciclib, to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general corporate purposes

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antolimab

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            AK002, an Anti-Siglec-8 antibody, depletes tissue eosinophils and improves dysphagia symptoms in patients with eosinophilic esophagitis.

            Cystic Fibrosis Foundation

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SNSP003

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Synspira Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 12, 2020

            Details:

            Synspira Therapeutics signed this agreement to support the development of SNSP003, Synspira’s orally delivered enzyme replacement therapy to treat Malabsorption Syndrome.